ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $69,115,831 | -6.9% | 2,546,638 | +5.5% | 0.02% | 0.0% |
Q2 2023 | $74,225,590 | -8.6% | 2,414,630 | +7.2% | 0.02% | -17.2% |
Q1 2023 | $81,189,931 | -8.2% | 2,253,400 | +0.6% | 0.03% | -14.7% |
Q4 2022 | $88,482,698 | -3.3% | 2,238,936 | -1.7% | 0.03% | -5.6% |
Q3 2022 | $91,514,000 | -2.5% | 2,277,597 | +2.0% | 0.04% | +9.1% |
Q2 2022 | $93,888,000 | +13.4% | 2,233,295 | +5.1% | 0.03% | +32.0% |
Q1 2022 | $82,784,000 | +12.7% | 2,124,840 | +15.3% | 0.02% | +13.6% |
Q4 2021 | $73,425,000 | +35.9% | 1,842,516 | +23.2% | 0.02% | +22.2% |
Q3 2021 | $54,031,000 | -10.4% | 1,495,030 | +1.6% | 0.02% | -10.0% |
Q2 2021 | $60,306,000 | -1.4% | 1,471,237 | +4.9% | 0.02% | -13.0% |
Q1 2021 | $61,180,000 | +158.1% | 1,402,572 | +196.2% | 0.02% | +155.6% |
Q4 2020 | $23,702,000 | +2039.2% | 473,579 | +1698.4% | 0.01% | – |
Q3 2020 | $1,108,000 | -65.6% | 26,333 | -60.3% | 0.00% | -100.0% |
Q2 2020 | $3,219,000 | – | 66,352 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |